BAF53a/ACTL6A Antibodies, cDNA Clones Research Reagents

All BAF53a/ACTL6A reagents are produced in house and quality controlled, including 1 BAF53a/ACTL6A Antibody, 17 BAF53a/ACTL6A Gene, 1 BAF53a/ACTL6A qPCR. All BAF53a/ACTL6A reagents are ready to use.

BAF53a/ACTL6A Antibody (1)

    BAF53a/ACTL6A cDNA Clone (17)

    NM_004301.3

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_001039033.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    BAF53a/ACTL6A qPCR Primer (1)

    BAF53a/ACTL6A の背景知識

    Increased Actin-like 6A (ACTL6A) expression has been implicated in the development of diverse cancers and recently associated with the Hippo signaling pathway, which is known to regulate biological properties, including proliferation, tissue regeneration, stem cell biology, as well as tumorigenesis. Here we first show that ACTL6A is upregulated in human gliomas and its expression is associated with glioma patient survival. ACTL6A promotes malignant behaviors of glioma cells in vitro and in orthotopic xenograft model. Moreover, effects of ACTL6A on glioma cells proliferation, migration, and invasion could be mediated by YAP/TAZ. These data indicate that ACTL6A may contribute to cancer progression by stabilizing YAP/TAZ and therefore provide a novel therapeutic target for the treatment of human gliomas. Actl6a knockdown reduced the pluripotency of embryonic stem cells (ESCs), and this reduction could not be rescued by the addition of ATP. The abundance of mitochondrially produced ATP affects stem cell pluripotency via Actl6a-mediated histone acetylation. ACTL6A gene mutation analysis should be considered in patients with intellectual disability, learning disabilities, or developmental language disorder.

    Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.